Merck wins US FDA OK for glaucoma treatment
This article was originally published in Scrip
Executive Summary
After an initial struggle to obtain the US FDA's approval for Zioptan (tafluprost ophthalmic solution) as a treatment to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension, Merck finally gained the agency's blessing on 13 February.